Key Market Drivers, Trends, and Forecast for the Global Non-Viral Drug Delivery Systems Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Much Is the Global Non-Viral Drug Delivery Systems Market Valued at Present and by 2029?
The market size for non-viral drug delivery systems has seen a swift expansion in the last few years. The industry, valued at $8.6 billion in 2024, is projected to escalate to $9.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.4%. Factors contributing to the growth during the historic phase include the escalating demand for more secure gene therapies, advancements in nanotechnology, a rise in chronic disease prevalence, an increased emphasis on personalized medicine, and enhanced regulatory support for non-viral platforms.
In the upcoming years, the market size for non-viral drug delivery systems is projected to witness significant growth, expanding to a worth of $16.72 billion by 2029, with a compound annual growth rate (CAGR) of 14.2%. The expected growth in the forecast period is attributed to factors such as the increasing acceptance of targeted therapies, augmented investments in drug delivery science, growing inclination for non-invasive treatments, incorporation of artificial intelligence and escalating demand for sustained-release formulations. The forecast period will also see major trends such as progress in nanocarrier technology, advanced biomaterials for improved delivery, breakthroughs in mRNA delivery platforms, smart drug delivery devices integration, and enhancements in gene editing delivery methods.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
#What Drivers Are Influencing Growth In The Non-Viral Drug Delivery Systems Market?
The surge in the need for tailored medications is projected to boost the expansion of the non-viral drug delivery systems market in the future. Personalized medicine, a medical plan customized to a person’s genetics, way of life, and surrounding environment, is witnessing a growing demand since it results in more efficient treatments by focusing on the exact triggers of illness in each individual. Non-viral mechanisms contribute to personalized medicine by securely administering drugs or genes to cells, minimizing hazards, and enhancing the accuracy of treatment. For illustration, the Personalized Medicine Coalition, an American non-profit establishment, declared that the FDA gave authorization for 16 novel personalized treatments for patients suffering from unusual diseases in February 2024, a marked increment from the six approvals in 2022. Consequently, the escalating demand for personalized medications is fuelling the development of the non-viral drug delivery systems market.
What Are The Main Segments Identified In The Non-Viral Drug Delivery Systems Market Research?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
What Are The Leading Trends And Opportunities In The Non-Viral Drug Delivery Systems Sector?
Leading companies in the non-viral drug delivery system market are pivoting towards innovative technologies like pre-optimized ionizable lipid mix systems to enhance the creation and delivery of RNA-rooted therapeutics. This technology is a formulation technique that aids the efficient encasing of RNA molecules into lipid nanoparticles, assuring heightened stability, safeguarding of payload, and targeted transportation for gene-based drug usages. For example, in September 2024, Cytiva, a biotechnology firm based in the U.S., unveiled an RNA delivery LNP kit that works harmoniously with its NanoAssemblr Ignite and Ignite+ platforms. This system comprises a ready-to-use ionizable lipid mix enabling quick RNA payload screening and efficient delivery validation, particularly in the light of developing vaccines for infectious diseases. The system effortlessly merges with automated microfluidic platforms, facilitates scalable production with GMP-grade components, and provides protocols and proof-of-concept data to help users throughout the journey from inception to clinical assessment.
Which Companies Play A Key Role In The Development Of The Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Get The Full Report Here:
What Are The Key Regional Developments Shaping The Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24628&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
